DOCSLIB.ORG

INSTIPRO Holding Movement of Top AMC for March 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
INSTIPRO Holding Movement of Top AMC for March 2021 INSTIPRO Holding Movement of Top AMC For March 2021 April 2021 About InstiPro List of AMC* Short Form Description: Aditya Birla Sun Life AMC Ltd. ABSL AMC InstiPro is a report on holdings movement of top asset management Axis Asset Management Co. Ltd. Axis AMC Canara Robeco Asset Management Co. Ltd. Canara AMC companies (selected) based out of India. It provide insights on institutional DSP Investment Managers Pvt Ltd. DSP AMC activities including list of companies, sector and industry where the Edelweiss Asset Management Ltd. Edelweiss AMC positions were increased, decreased, sold out or added over a specific Franklin Templeton Asset Management Ltd. Franklin AMC HDFC Asset Management Co. Ltd. HDFC AMC duration of 1 month. ICICI Prudential Asset Management Co. Ltd. ICICI Pru AMC IDFC Asset Management Co. IDFC AMC Invesco Asset Management (India) Pvt Ltd. Invesco AMC Kotak Mahindra Asset Management Co. Ltd. Kotak AMC Period: 1st-31st March’21 L&T Investment Asset Management Co. Ltd L&T AMC Mirae Asset Global Investments (India) Pvt Ltd. Mirae AMC Holding Movement Period: 1 Month Motilal Oswal Asset Management Co. Ltd. Motilal AMC Currency & Denomination: INR in Million Nippon Life Asset Management Ltd. Nippon AMC Shares: In Thousands (Rounded off) Principal Asset Management Pvt Ltd. Principal AMC SBI Funds Management Pvt Ltd. SBI Funds Share Movement: Based on number of shares bought/sold by AMC Sundaram Asset Management Co. Ltd. Sundaram AMC Database: FactSet Tata Asset Management Ltd. TATA AMC UTI Asset Management Co. Ltd. UTI AMC *The above AMC cover ~70% of the overall AMC’s AUM. The data list of Note: Position movements are not net-off on overall activity. AMC excludes insurance companies and pension funds. Source: FactSet & KRChoksey Research Performance Analysis – By Sector – March’21 - Decreased & Sold-Out Positions In a trend reversal from preceding months, March 21 experienced net inflows into equity mutual funds. Utilities (Gail, NTPC, ONGC, Indian Oil Corporation) along with metal companies (Vedanta, Hindalco) remained some of the top large cap counters which were sold by MFs during March 21 Focus Sectors Top focus companies – Decreased/Sold-Out Positions Figures in INR Mn Transportation, -140 Interglobe Aviation | Container Corp |Adani Port | VRL Logistics Note: The value is based on the combined price (average) for all securities bought/sold during Mar’21. Electronic Technology, -158 Honeywell | BEL | HAL | Astra Utilities, -4,288 GAIL | Power Grid | Tata Power | NTPC Non-Energy Minerals, -5,099 Vedanta | Grasim | Ultratech Cement | Ambuja Cements Commercial Services, -6,102 Info Edge | Teamlease | ICRA | Oracle Finance, -6,344 HDFC Bank | SBI | Bajaj Finance | HDFC Retail Trade, -7,405 Avenue Supermarts | Aditya Birla (Pantallons) | Trent | Dixon Health Technology, -9,683 Divis | Sun Pharma | Cipla | Aurobindo Producer Manufacturing, -13,805 Astal Poly | Eicher Motors | Endurance | Motherson Sumi Process Industries, -16,444 Pi Industries | Asian Paints | Grindwell | Tata Chemicals Consumer Durables, -18,136 Maruti Suzuki | M&M | Titan | Crompton Greaves Consumer Non-Durables, -21,514 HUL | ITC | Tata Consumer | Pi Industries Source: FactSet & KRChoksey Research Performance Analysis – By Sector – March’21 – Increased & New Positions MFs increased allocation to sectors in IT, Healthcare, Chemicals and Cement on a month on month basis; whereas Banks (mainly PSU) along with oil & gas, utilities and capital goods saw decrease in weightages on a month-on-month basis in March 21. Top focus companies – Increased/New Positions Focus Sectors – Overall Movement Figures in INR Mn BPCL | ONGC | RIL | Coal India Energy Minerals, 18,971 Bharti Airtel | Tata Communications | Railtel Corp Communications, 14,142 TCS | Infosys | HCL Tech | Wipro Technology Services, 7,358 Tata Motors | Bajaj Auto | M&M | Maruti Suzuki Consumer Durables, 7,184 Varroc | Adani Enterprises | Aegis Logistics | MMTC Distribution Services, 3,498 Max Healthcare | Apollo Hospital | Fortis HealthCare | Thyrocare Health Services, 2,902 L&T | Voltas | Indraprastha | Petronet Industrial Services, 388 Note: The value is based on the combined price (average) for all securities bought/sold during March’21. Source: FactSet & KRChoksey Research Performance Analysis – By Market Capitalization – March’21 MFs bought strongly in select mid-caps and small-caps during the March 21 including names such as Max Healthcare Institute, Wabco India, and MTAR Technologies where SBI MF, HDFC AMC and ICICI Prudential AMC added positions during month of March 21. Increased (INR Mn) Decreased (INR Mn) Total Companies: 586 Total Companies: 496 Mid Cap, Large Cap, 1,00,549 Large Cap, 3,68,879 Mid Cap, No of Co: 149 4,04,524 No of Co: 149 39,905 No of Co: 164 No of Co: 146 Small Cap, Small Cap, 22,973 26,850 No of Co: 273 No of Co: 201 New Position (INR Mn) Mid Cap, Sold Out (INR Mn) Total Companies: 110 26,180 Total Companies: 100 Small Cap, No of Co: 33 3,283 No of Co: 53 Small Cap, Mid Cap, 15,974 Large Cap, 2,489 Large Cap, No of Co: 39 13,436 No of Co: 28 2,103 No of Co: 38 No of Co: 19 Note: The value is based on the combined price (average) for all securities bought/sold during March’21. Large Cap: >2.75Mn Mid Cap: 0.75 – 2.75Mn Small Cap: <0.75Mn Source: FactSet & KRChoksey Research New Positions - Top Picks by AMC. – March’21 Mkt. Cap. INR 2,75,000 Mn & above In Mn In '000 Between INR 75,000 - 2,75,000 Mn In Mn In '000 Below INR 75,000 Mn In Mn In '000 Large Cap Price Mkt.Cap Shares Mid Cap Price Mkt. Cap Shares Small Cap Price Mkt.Cap Shares Tata Communications Ltd 1,063 3,02,827 8,208 Wabco India Ltd 6,588 1,24,958 1,892 Mtar Technologies Ltd 1,024 31,495 2,928 Au Small Finance Bank Ltd 1,226 3,82,852 731 Max Healthcare Institute Ltd 206 1,99,033 43,589 Varroc Engineering Ltd 365 55,714 7,121 Sbi Cards & Payment Services Ltd 929 8,74,077 950 Fortis Healthcare Ltd 199 1,50,237 7,737 Craftsman Automation Ltd 1,418 29,957 1,293 Grasim Industries Ltd 1,452 9,55,411 325 L&T Finance Holdings Ltd 96 2,36,449 5,221 Nazara Technologies Ltd 1,465 44,612 1,165 Yes Bank Ltd 16 3,90,857 26,295 Granules India Ltd 303 75,120 1,318 Suryoday Small Finan Bank Ltd 274 29,059 5,522 Bank Of Baroda Ltd 74 3,83,456 3,766 Cesc Ltd 593 78,606 603 Easy Trip Planners Ltd 210 22,767 6,188 Godrej Properties Ltd 1,408 3,91,441 190 Oberoi Realty Ltd 575 2,09,217 537 Laxmi Organic Industries Ltd 174 45,943 7,210 Adani Enterprises (Exports) Ltd 1,031 11,33,739 254 Jsw Energy Ltd 88 1,44,483 2,538 Kalyan Jewellers India Ltd 68 70,147 9,715 Indus Towers (Bharti) Ltd 245 6,61,068 966 Rec (Rural Electrification) Ltd 131 2,59,208 1,614 Anupam Rasayan India Ltd 490 49,007 1,332 Colgate Palmolive (India) Ltd 1,560 4,24,189 119 Coforge (Niit) Ltd 2,929 1,77,479 66 Welspun Corp Ltd 139 36,302 2,560 Tata Power Co Ltd 103 3,29,759 1,026 Crisil Ltd 1,836 1,33,454 101 Den Networks Ltd 49 23,503 6,000 Mrf Ltd 82,219 3,48,701 1 Tata Elxsi Ltd 2,693 1,67,735 51 Kpit Technologies Ltd 177 48,523 1,435 Apollo Hospitals Enterprise Ltd 2,903 4,17,392 25 National Aluminium Co Ltd 54 99,178 2,346 Repco Home Finance Ltd 337 21,080 445 Nmdc Ltd 135 3,96,364 409 Cg Power & Indl Sol Ltd 67 89,445 1,253 Ksb (Pumps) Ltd 895 31,165 112 Jindal Steel & Power Ltd 344 3,50,733 160 Chambal Fertilisers & Ltd 229 95,221 300 Orient Refractories Ltd 227 27,236 225 Highlighted cells are covered by KRChoksey Research Source: FactSet & KRChoksey Research For reference Stock Price and Mkt. Cap data is as of 31st March 2021 Increased - Top Picks by AMC. – March’21 Mkt. Cap. INR 2,75,000 Mn & above In Mn In '000 Between INR 75,000 - 2,75,000 Mn In Mn In '000 Below INR 75,000 Mn In Mn In '000 Large Cap Price Mkt.Cap Shares Mid Cap Price Mkt. Cap Shares Small Cap Price Mkt.Cap Shares Bharat Petroleum Corp Ltd 428 9,28,332 63,987 Aia Engineering Ltd 2,048 1,93,163 1,504 Varroc Engineering Ltd 365 55,714 5,748 Axis Bank Ltd 698 21,36,709 27,598 Zee Entertainment (Telefilms) Ltd 203 1,95,126 13,245 Hathway Cable & Datacom Ltd 26 45,403 77,174 Tata Consultancy Services Ltd 3,178 1,17,54,106 5,104 City Union Bank Ltd 156 1,15,182 12,181 Vip Industries Ltd 354 50,055 3,352 Bharti Airtel (Tele Ventures) Ltd 517 28,41,026 27,337 Ipca Laboratories Ltd 1,903 2,41,329 944 Techno Electric & Enginee Ltd 306 33,655 2,965 Bank Of Baroda Ltd 74 3,83,456 1,77,745 Crompton Greaves Consumer Ltd 394 2,46,997 3,140 Birla Corp Ltd 950 73,190 835 Sbi Life Insurance Co Ltd 881 8,80,562 13,857 National Aluminium Co Ltd 54 99,178 21,639 Pnc Infratech Ltd 257 66,033 3,010 Infosys (Infosys Tech) Ltd 1,368 58,27,519 8,911 Cummins India Ltd 920 2,54,913 1,200 Angel Broking Ltd 291 23,820 2,646 Tata Steel Ltd 812 9,30,413 13,315 Bata India Ltd 1,405 1,80,536 737 Advanced Enzyme Techno Ltd 345 38,530 1,969 Oil & Natural Gas Corp Ltd 102 12,85,076 98,542 Coforge (Niit) Ltd 2,929 1,77,479 348 Sterling & Wilson Solar Ltd 258 41,309 2,577 Sbi Cards & Payment Services Ltd 929 8,74,077 9,901 Tata Chemicals Ltd 751 1,91,386 1,350 Just Dial Ltd 862 53,361 732 State Bank Of India Ltd 364 32,51,683 24,428 Persistent Systems Ltd 1,919 1,46,640 521 Mtar Technologies Ltd 1,024 31,495 543 Hdfc Bank Ltd 1,494 82,33,607 5,776 Torrent Power Ltd 424 2,03,661 2,260 Bajaj Consumer Care Ltd 260 38,346 2,037 Dr Reddys Laboratories Ltd 4,516 7,50,908 1,822 Sun Tv Network Ltd 470 1,85,259 1,913 Equitas Small Finance Bank Ltd 60 68,400 8,448 Power Grid Corp Of India Ltd 216 11,28,192 37,044 Polycab India Ltd 1,380 2,05,797 639 Jk Lakshmi Cement Ltd 433 50,892 1,138 Kotak Mahindra Bank Ltd 1,754 34,75,764 4,406 Wabco India Ltd 6,588 1,24,958 133 Greenpanel Industries Ltd 160 19,627 2,988 Highlighted cells are covered by KRChoksey Research Source: FactSet & KRChoksey Research For reference Stock Price and Mkt.
Load more

Recommended publications
  • Healthcare Sector in India Flanders Investment & Trade Market Survey
    HEALTHCARE SECTOR IN INDIA FLANDERS INVESTMENT & TRADE MARKET SURVEY Healthcare Sector in India Flanders Investment & Trade Economic Representation of Flanders c/o Embassy of Belgium 50 - N, Shantipath, Chanakyapuri New Delhi - 110 021 India [email protected] T: +91 11 42 42 81 00 F: +91 11 42 42 81 10 Studie Healthcare Sector in India | juni 2015 1 2 TABLE OF CONTENTS ICT in Healthcare Services in India ................................................................................................. 8 Introduction ......................................................................................................................................... 8 Healthcare Information & Communication Technology (HICT) ...................................................... 9 Patient Monitoring & Tracking ........................................................................................................ 9 Healthcare Information Technology (HIT) ..................................................................................... 10 National Health Policy ................................................................................................................... 10 Health Information Management Systems (HIMS) ....................................................................... 10 Grading of Indian States for the use of ICT in Hospitals ................................................................ 12 Telemedicine ....................................................................................................................................
    [Show full text]
  • FHL Annual Report 2020-21
    ANNUAL REPORT 2020-2021 COMPANY INFORMATION CONTENTS BOARD OF DIRECTORS CORPORATE OVERVIEW CLINICAL EXCELLENCE Chairman 02 Introduction 66 Dedicated to Serve Responsibly Ravi Rajagopal (Independent Director) 04 Vision and Mission AWARDS AND ACCOLADES 06 Values Vice-Chairman 74 Inspired By Recognitions Shirish Moreshwar Apte (Non-Executive Director) 08 Key Performance Highlights 2020-21 HUMAN RESOURCES Managing Director and CEO BOARD OF DIRECTORS 78 Inspiring Trust Through the People Power Dr. Ashutosh Raghuvanshi 10 Fortis Healthcare Limited 12 SRL Limited Non-Executive Directors STATUTORY REPORTS Dilip Kadambi MANAGEMENT COMMUNIQUE 84 Director’s Report Dr. Farid Bin Mohamed Sani 136 Report on Corporate Governance 14 From the Chairman’s Desk Heng Joo Joe Sim 164 Business Responsibility Report Joerg Ayrle 18 MD & CEO’s Message (FHL) 175 Management Discussion and Analysis Report Dr. Kelvin Loh Chi-Keon 22 CEO’s Message (SRL) Takeshi Saito FINANCIAL STATEMENTS COVID-19 AND OUR RESPONSE Independent Directors 26 A Clear and Compelling Purpose 191 Standalone Financials Indrajit Banerjee 283 Consolidated Financials Shailaja Chandra FORTIS HEALTHCARE LIMITED Suvalaxmi Chakraborty 32 Inspiring Trust Across the Nation Chief Financial Officer OUR TRANSFORMATION Vivek Kumar Goyal 38 The New Journey Company Secretary and Compliance Officer FINANCIAL HIGHLIGHTS Sumit Goel 40 Performance Snapshot Auditors CLINICAL FOCUS B S R & Co. LLP Chartered Accountants 44 New Clinical Offerings Fortis Healthcare Limited 46 Speciality Mix CIN: L85110PB1996PLC045933
    [Show full text]
  • Fortis Healthcare Limited
    FORTIS HEALTHCARE LIMITED Earnings Presentation – Q2FY21 November 12, 2020 Disclaimer This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction. This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements.
    [Show full text]
  • Fortis Healthcare Limited Investor Presentation – Q3 FY2013
    Fortis Healthcare Limited Earnings Presentation – FY20 and Q4 FY20 June 17, 2020 Disclaimer This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction. This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements.
    [Show full text]
  • Franklin India Fund LU0231204701 31 August 2021
    Franklin Templeton Investment Funds India Equity Franklin India Fund LU0231204701 31 August 2021 Fund Fact Sheet For Professional Client Use Only. Not for distribution to Retail Clients. Fund Overview Performance Base Currency for Fund USD Performance over 5 Years in Share Class Currency (%) Total Net Assets (USD) 1.44 billion Franklin India Fund I (acc) USD MSCI India Index-NR Fund Inception Date 25.10.2005 200 Number of Issuers 45 180 Benchmark MSCI India Index-NR 160 Investment Style Blend Morningstar Category™ India Equity 140 Summary of Investment Objective 120 The Fund aims to achieve long-term capital appreciation by 100 principally investing in equity securities of companies of any size located or performing business predominately in India. 80 Fund Management 60 08/16 02/17 08/17 02/18 08/18 02/19 08/19 02/20 08/20 02/21 08/21 Sukumar Rajah: Singapore Discrete Annual Performance in Share Class Currency (%) Ratings - I (acc) USD 08/20 08/19 08/18 08/17 08/16 08/21 08/20 08/19 08/18 08/17 Overall Morningstar Rating™: I (acc) USD 53.68 3.31 -9.75 -0.35 12.92 Asset Allocation Benchmark in USD 53.15 3.00 -7.64 7.12 17.46 Performance in Share Class Currency (%) Cumulative Since 1 Mth 3 Mths 6 Mths YTD 1 Yr 3 Yrs 5 Yrs Incept I (acc) USD 8.00 10.33 21.17 24.53 53.68 43.28 61.24 518.48 % Benchmark in USD 10.94 11.12 22.35 25.75 53.15 45.68 83.30 371.80 Equity 103.05 Category Average 7.59 10.63 20.10 25.82 52.53 37.90 66.00 355.61 Cash & Cash Equivalents -3.05 Calendar Year Performance in Share Class Currency (%) 2020 2019 2018 2017 2016 I (acc) USD 13.92 8.35 -14.74 39.23 2.82 Benchmark in USD 15.55 7.58 -7.31 38.76 -1.43 Past performance is not an indicator or a guarantee of future performance.
    [Show full text]
  • 20210506001-Equity Outlook May 2021-BROCHURE
    EQUITY M AY 2 0 2 1 13.2% 48.4% -0.4% Nifty 50 - Last 5 years Nifty 50 - Last 1 year Nifty 50 - MTD (CAGR) (Absolute) (Absolute) QUICK TAKE Equity market valuations are broadly reasonable We remain bullish on equities Investors are suggested to have their adjusted for the cyclical low in earnings and from a medium to long term asset allocation plan based on one’s risk potential for revival going forward. perspective. appetite and future goals in life. KEY HIGHLIGHTS MARKETS Equity markets saw yet another volatile month driven by news Markets have entered a period of consolidation over the past few flow and policy action. The broader markets continued to weeks as they digest earnings and news flow. While the global outperform frontline stocks driven by high quality mid and small picture is positive, in India the key aspect to monitor is the peak of caps finding favour with investors. Frontline benchmarks, S&P the second wave and the progress of the vaccination drive. From a BSE Sensex & NIFTY 50 ended the month down 1.5% & 0.4% valuations standpoint, the beta normalization is likely to give way respectively. NIFTY Midcap 100 registered a gain of 2.1% while to fundamentals based long term growth. To that effect earnings NIFTY Smallcap 100 rose 5.6%. After a strong start to the year, so far have brought valuations to long term averages. India has lagged its global peers over the last few months Our portfolio companies today encompass a cross section of understandably so on account of the Covid news irking foreign growth ideas ideally suited to benefit from gaps left by weaker investors.
    [Show full text]
  • Extract of Annual Return As on the Financial Year Ended on March 31
    Integrated Annual Report 2018-19 Annexure 8 to Board’s Report Form No. MGT-9 Extract of Annual Return as on the financial year ended on March 31, 2019 ReportIntegrated [Pursuant to Section 92(3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014] I. Registration and Other Details i) CIN L24239MH1939PLC002893 ii) Registration Date January 23, 1939 iii) Name of the Company TATA CHEMICALS LIMITED iv) Category / Sub-Category of the Company Public Company/ Limited by shares v) Address of the Registered Office and contact details Bombay House 24, Homi Mody Street, Fort, Mumbai – 400 001 Telephone: + 91 22 6665 8282 Fax: +91 22 6665 8144 email: [email protected] website: www.tatachemicals.com vi) Whether listed company Yes vii) Name, Address and Contact details of Registrar & M/s.TSR Darashaw Limited Statutory Reports > Share Transfer Agents (RTA) Unit: Tata Chemicals Limited 6 – 10 Haji Moosa Patrawala Industrial Estate 20 Dr. E Moses Road Near Famous Studio Mahalaxmi, Mumbai – 400 011 Telephone: +91 22 6656 8484 Fax: +91 22 6656 8494 Report Board‘s email: [email protected] website: www.tsrdarashaw.com II. Principal Business Activities of the Company All the business activities contributing 10% or more of the total As per Annexure A turnover of the company shall be stated III. Particulars of Holding, Subsidiary and Associate Companies As per Annexure B IV. Shareholding Pattern (Equity Share Capital Breakup as Percentage of Total Equity) i) Category-wise Shareholding ii) Shareholding of Promoters iii) Change in Promoters’ Shareholding As per Annexure C (please specify, if there is no change) iv) Shareholding Pattern of top ten Shareholders (other than Financial Statements Financial Directors, Promoters and Holders of GDRs and ADRs) v) Shareholding of Directors and Key Managerial Personnel V.
    [Show full text]
  • INFO EDGE Recruitment Continues to Disappoint
    RESULT UPDATE INFO EDGE Recruitment continues to disappoint India Equity Research| IT Info Edge’s (IEL) Q2FY14 revenue at INR1,230mn was below our EDELWEISS 4D RATINGS estimated INR1,268mn. However, EBITDA margin at 35.5%, jumped Absolute Rating REDUCE 500bps QoQ primarily due to lower S&M expenses. Disappointment in Rating Relative to Sector Underperformer recruitment continued as it posted a tepid 8.3% YoY revenue growth (up Risk Rating Relative to Sector Medium 0.2% QoQ). Though IEL does not anticipate a pick-up in hiring activity in Sector Relative to Market Overweight the near term, decent recruitment by IT companies and market share gains are supporting growth. Non-recruitment segments grew 45% YoY MARKET DATA (R: INED.BO, B: INFOE IN) and the management intends to invest further in these to provide growth CMP : INR 345 impetus. We do not perceive any uptick in hiring activities given the Target Price : INR 310 uncertain macro environment. We maintain ‘REDUCE’ with TP of INR310 52-week range (INR) : 405 / 276 (19x FY15E Standalone EPS). Share in issue (mn) : 109.2 M cap (INR bn/USD mn) : 38/ 621 Naukri continues to disappoint Avg. Daily Vol.BSE/NSE(‘000) : 92.2 Hiring activity has been slow given the sustained uncertain macro environment which is amply reflected from Naukri’s YoY subdued growth (below 20% in past six quarters). SHARE HOLDING PATTER N (%) However, the management stated decent recruitment by IT companies and market Current Q1FY14 Q4FY13 share gains are supporting growth. Revenue from this segment grew 8.3% YoY, with Promoters * 52.2 52.2 52.2 operating margin at 50.7% (50.3% in Q1FY14).
    [Show full text]
  • Inner 25 India Pharma & Healthcare Fund
    Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata India Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Glenmark Pharmaceuticals Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services Sanofi India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Hospitals Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Fortis Healthcare Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd.
    [Show full text]
  • Annual Report 2018-19 80Th Year Contents
    Accelerating focussed growth Integrated Annual Report 2018-19 80th Year Contents Integrated Report Deep innovation expertise to harness the 01-57 best of science and serve the society. 01 Company Overview A passion to consistently push beyond 06 Our Diversified Science Led Portfolio 08 Performance Highlights for FY 2018-19 existing limits and rise above. 10 Board of Directors Combine innovation and passion with scale 12 Management Team and accelerated growth happens. 13 MD & CEO's Message 14 Integrated Value Chain This is how Tata Chemicals has emerged to be one of the world’s most reputed brands, revolutionising the 16 Business Model Explaining the Interlinkage of Capitals industry segments it has operated in its 18 Our Formula for Accelerating 80-year journey. Focussed Growth As we continue to nurture our inherent strengths, 21 Managing Risks, Maximising Returns we are undertaking many initiatives to accelerate our 24 Listening to and Engaging growth in focussed areas. with the Stakeholders 25 Addressing Material Issues Our multi-pronged strategy of customer-centric 26 Basic Chemistry Business product development and expansion into white spaces in our Consumer Products Business and capacity 32 Consumer Products Business augmentation programmes in our Specialty Products 38 Specialty Chemicals Business Business has laid a strong foundation for growth. 45 Intensifying Focus on Health & Safety Aligning our organisational structure and strategies 46 Innovating for a Better World with the revised segment reporting and the exit from 48 Growing Together non-core businesses has simplified our portfolio and are 50 Our Commitment to driving stronger synergies. Strong innovation drive is Sustainable Growth enabling us to tap the emerging areas and 53 Corporate Social Responsibility nurture the newly-seeded portfolio.
    [Show full text]
  • Info Edge (India) Ltd
    Info Edge (India) Ltd. April 9, 2019 Analyst: Kunal Bhatia Initiating Coverage @ Dalal & Broacha BUY Highest Market Share by traffic coupled with robust industry growth in flagship products (Naukri and 99acres) and investee companies to drive performance Current Price 1,856 Naukri.com Target Price Naukri is benefiting from strong hiring and churning trends in the IT services sector in FY18 2,423 and 9MFY19 (IT sector directly contributes 31% to Naukri.com’s revenues which in turn Upside/Downside 31% contributes 71% to Total standalone sales of Info Edge). Management stated that top 4-5 IT services companies contribute 4-5% to topline whereas Mid to Small tier companies 52 Week Range 1,126/1,930 contribute a larger chunk. Net Additions have been strong in mid to bottom bucket of the companies as well. Naukri revenues reported a growth of 17% YoY in 9MFY19 whereas 5 Key Share Data year CAGR between FY14 and FY18 stood at 12.4% Market M M Market Cap (Rs.bn) 229 99acres (17% of standalone revenues) Market Cap (US$ mn) 3319 99acres has also reported steady performance in the past 2 quarters after the real estate No of o/s shares (mn) 122 industry has moved past the overhang of De-mon, GST and RERA. 99acres grew 40% YoY in Face Value 10 9MFY19 whereas 5 year CAGR was 11.9%. The split between Brokers : Builders is 50 : 50 and company maintains that participation from brokers compared to builders has increased Monthly Avg. 343.8 massively during 9MFY19. Management is of the view that the real estate market has vol(BSE+NSE) Nos’000 stabilized, which is evident through an increase in transactions in Q3FY19 and heightened BSE Code 532777 activity of the broker segment (43% in FY16 to 51% as of December 2018).
    [Show full text]
  • “Re-Engineering Indian Healthcare”
    “Re‐engineering Indian Healthcare” Aug 31 ‐Sep 1, 2016 FICCI, New Delhi PROGRAM As on August 30, 2016 Day 1 – Wednesday, August 31, 2016 8:30 am Registration 10:00 am – 11:20 am Opening Session Session Moderator Ms Shobha Mishra Ghosh, Senior Director, FICCI Welcome Address Dr Nandakumar Jairam, Chair, FICCI Health Services Committee; Chairman, NABH & Chairman & Group Medical Director, Columbia Asia Hospitals India Presentation on 10th year of HEAL Ms Shobha Mishra Ghosh, Senior Director, FICCI Theme Address Mr Vishal Bali, Chair, FICCI HEAL 2016 Organizing Committee; Co‐Chair, FICCI Health Services Committee & Asia Head ‐ Healthcare, TPG Growth Keynote Address Mr Sunil Kant Munjal, Jt. Managing Director, Hero Motocorp Ltd. & Chairman, Hero Corporate Service Ltd. Release of Knowledge Paper: FICCI‐ EY paper on ‘Nursing Reforms: A paradigm shift for bright future’ Announcement of Poster Presentation Competition on the Theme “Re‐ engineering Indian Healthcare’ Keynote Address Mr C K Mishra, Secretary, Ministry of Health & Family Welfare, GoI Vote of Thanks Dr A Didar Singh, Secretary General, FICCI On Dais Mr Ashok Kakkar, Co‐Chair, FICCI Health Services Committee and Senior MD, Varian Medical Systems International India Pvt Ltd 11:20 am ‐ 11:45 am Tea Break 1 “Re‐engineering Indian Healthcare” Aug 31 ‐Sep 1, 2016 FICCI, New Delhi 11:45 am – 12:30 pm Keynote Session Moderator: Dr Nandakumar Jairam, Chair, FICCI Health Services Committee; Chairman, NABH & Chairman & Group Medical Director, Columbia Asia Hospitals India Presentation on the
    [Show full text]